Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT00704158 (Clinical Trial / Glembatumumab vedotin / CDX-011 / CR011-vcMMAE)

Study Title
Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer (NCT00704158)

Trial Description
This study will evaluate the safety and tolerability of CR011-vcMMAE (also known as glembatumumab vedotin or CDX-011) in patients with locally advanced and metastatic breast cancer. CR011-vcMMAE will be administered intravenously (IV) once every 3 weeks (q3w) to cohorts of 3-6 patients to confirm the maximum tolerated dose (MTD) in breast cancer patients. Once the MTD is confirmed, up to 25 patients with locally advanced or metastatic breast cancer will be enrolled into the Phase II portion of the trial to further evaluate the safety and efficacy of CR011-vcMMAE.

This trial is sponsored by Celldex Therapeutics. [1]

Study Data

  • Condition: Breast Cancer
  • Interventions:
    • Drugs used in this trial
  • Phase: I & II
  • Enrollment: 42
  • Start: June 2008
  • Completion: June 2011
  • Last verified: February 2015

Study Schematic 

NCT00704158 (Clinical Trial / Glembatumumab vedotin / CDX-011 / CR011-vcMMAE)


Last Editorial review: July 29, 2016

Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar